搜尋
Repligen Corp
RGEN添加自選
135.800USD
-1.200-0.88%
交易中 （美東）報價延遲15分鐘
7.65B總市值
148.67本益比TTM
關於 Repligen Corp 公司
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Repligen Corp簡介
公司代碼RGEN
公司名稱Repligen Corp
上市日期Apr 29, 1986
CEOLoeillot (Olivier)
員工數量1778
證券類型Ordinary Share
年結日Apr 29
公司地址Building 1, Suite 100
城市WALTHAM
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02453
電話17814499560
網址https://www.repligen.com/
公司代碼RGEN
上市日期Apr 29, 1986
CEOLoeillot (Olivier)
Repligen Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
Independent Director
Independent Director
--
--
Mr. James R. Bylund
Mr. James R. Bylund
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
常見問題
Repligen Corp的前五大股東是誰？
Repligen Corp的前五大股東如下：Ms. Karen A. Dawes
有多少機構持有Repligen Corp(RGEN)的股份？
截至2026Q1，共有1067家機構持有Repligen Corp的股份，合計持有的股份價值約為65.93M，占公司總股份的116.89% 。與2025Q4相比，機構持股有所增加，增幅為-2643397.00。
哪個業務部門對Repligen Corp的收入貢獻最大？
在2026Q1，Product revenue - Filtration products業務部門對Repligen Corp的收入貢獻最大，創收402.79M，占總收入的54.58% 。
